Chronic HCV Infection Clinical Trial
Official title:
A Phase Ⅱ/Ⅲ Study to Evaluate Efficacy and Safety of Antaitavir Hasophate Capsules in Combination With Yiqibuvir Tablets in Adult Subject With Chronic HCV Infection
The safety, tolerability and antiviral activity of Antaitavir Hasophate in Combination With Yiqibuvir in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) infection
Phase II: Exploring the efficacy and safety of different doses of Antaitavir Hasophate combined with fixed-dose Yiqibuvir in the treatment of adult patients with chronic hepatitis C for 12 weeks, providing a basis for the design and implementation of phase III clinical trials. Phase III: Confirmation of the efficacy and safety of Antaitavir Hasophate combined with Yiqibuvir in the treatment of adult patients with chronic hepatitis C for 12 weeks, providing a sufficient basis for drug registration and clinical use. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01938430 -
Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
|
Phase 2 | |
Completed |
NCT01975675 -
Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection
|
Phase 3 | |
Completed |
NCT01984294 -
Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection
|
Phase 2 | |
Completed |
NCT02074514 -
Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection
|
Phase 3 | |
Completed |
NCT03458481 -
Phase 2 Study of Yimitasvir Phosphate Capsules
|
Phase 2 | |
Completed |
NCT02010255 -
Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant
|
Phase 2 | |
Recruiting |
NCT00842205 -
Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection
|
N/A | |
Completed |
NCT02973503 -
Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis
|
Phase 3 | |
Recruiting |
NCT03540212 -
Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus
|
Phase 2/Phase 3 | |
Completed |
NCT02021656 -
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection
|
Phase 3 | |
Completed |
NCT02021643 -
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection
|
Phase 3 | |
Completed |
NCT02120300 -
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders
|
Phase 2 | |
Completed |
NCT03487107 -
Phase 3 Study of Yimitasvir Phosphate Capsules
|
Phase 3 |